Skip to content

Myasthenia Gravis Foundation of America Global MG Patient Registry

Myasthenia Gravis Foundation of America Global MG Patient Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06617741
Acronym
MGFAPR
Enrollment
3800
Registered
2024-09-27
Start date
2013-10-12
Completion date
2029-09-19
Last updated
2024-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthaenia Gravis, Myasthenia, Myasthenia Gravis, Myasthenia Gravis, Adult Form, Myasthenia Gravis Associated with Thymoma, Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, Myasthenia Gravis Generalised, Myasthenia Gravis, Generalized, Myasthenia Gravis, MuSK, Myasthenia Gravis, Ocular, Myasthenia Gravis, Thymectomy, Myasthenia Gravis with Exacerbation (Disorder)

Keywords

myasthenia, patient registry, MGFA, Myasthenia Gravis Foundation of America, myasthenia gravis

Brief summary

The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States. The main questions it aims to answer are: * How and when are people with MG diagnosed? * What are the most common symptoms associated with MG? * What treatments are being used to treat MG? * What are the impacts of MG on activities of daily living, employment and quality of life? * What are the experiences with exacerbation, hospitalization and healthcare access for people with MG? Participants will answer a survey to enroll in the study, and be invited to fill out an update survey twice a year.

Detailed description

This is a longitudinal, observational, patient reported registry.

Interventions

None listed

Sponsors

Alira Health
CollaboratorOTHER
Myasthenia Gravis Foundation of America
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age over 18 * positive MG diagnosis

Exclusion criteria

* age under 18 * misdiagnosed with MG

Design outcomes

Primary

MeasureTime frameDescription
Diagnosis of MGAt enrollmentWhether the patient has a confirmed MG diagnosis.

Countries

United States

Contacts

Primary ContactNational Director, Patient Registry
gmvalo@myasthenia.org8005415454

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026